Allergan board unanimously rebuffs latest acquisition offer from Valeant, Pershing Square
Allergan's board is unanimously rejecting the latest takeover bid from Valeant Pharmaceuticals, and the Botox maker says the offer isn't even worth talking about.
Allergan says a May 30 offer from the Canadian drugmaker and activist investor Bill Ackman's Pershing Square Capital Management still substantially undervalues Allergan Inc. and creates too much risk for shareholders. Allergan also says the deal doesn't offer enough value to warrant discussions between the companies.
That deal amounts to around $53 billion. It includes $72 in cash and a portion of Valeant Pharmaceuticals International Inc. stock for each Allergan share and was up from a previous bid that involved $58.30 in cash and the stock portion.
Ackman is a big Allergan shareholder. He has said he will move to replace most of Allergan's board.
Read more Business News
- Coke smuggler gets 14 yearsKelowna - 1:31 pm
- Cops warn public about 'ICE'Kelowna - 1:15 pm
- Where is Batman?Penticton / S. Okanagan - 1:33 pm
- Man falls to deathPenticton / S. Okanagan - 2:30 pm
|QHR Technologies Inc||1.22||-0.04|
|Anavex Life Sciences||0.1804||-0.0036|
|Copper Mountain Mining||2.29||-0.13|
|Sunrise Resources Ltd||0.065||+0.045|
|Mission Ready Services||0.31||-0.01|
Part 2 of 2 to read Part 1, click here. 5. Dial down your vacations. New York is out. Maybe Buffalo. For West coast, maybe Seattle instead of Hawaii. Use sites like Airbnb (aribnb.ca) to find ch...
Niche food producer “Sweets from the Earth” thrives using innovation, uniqueness and an unwavering focus on quality. A neighbour’s stew turned Ilana Kadonoff off meat at the age of s...
Recently I had the privilege of working alongside André Voskuil, a local guru in the world of Alternative Financing. André has quite the reputation in the world of direct investments as ...